DE03713610T1 - Neue kristallformen von atorvastatin-hemicalcium und verfahren zu deren herstellung, sowie neue verfahren zur herstellung der formen i, viii und ix von atorvastatin-hemicalcium - Google Patents

Neue kristallformen von atorvastatin-hemicalcium und verfahren zu deren herstellung, sowie neue verfahren zur herstellung der formen i, viii und ix von atorvastatin-hemicalcium Download PDF

Info

Publication number
DE03713610T1
DE03713610T1 DE03713610T DE03713610T DE03713610T1 DE 03713610 T1 DE03713610 T1 DE 03713610T1 DE 03713610 T DE03713610 T DE 03713610T DE 03713610 T DE03713610 T DE 03713610T DE 03713610 T1 DE03713610 T1 DE 03713610T1
Authority
DE
Germany
Prior art keywords
atorvastatin hemicalcium
forms
new
viii
production
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
DE03713610T
Other languages
English (en)
Inventor
Limor Tessler
Judith Aronhime
Revital Lifshitz-Liron
Dalia Maidan-Hanoch
Nir Hasson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Teva Pharmaceutical Industries Ltd
Original Assignee
Teva Pharmaceutical Industries Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Teva Pharmaceutical Industries Ltd filed Critical Teva Pharmaceutical Industries Ltd
Publication of DE03713610T1 publication Critical patent/DE03713610T1/de
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/32—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D207/325—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms with substituted hydrocarbon radicals directly attached to the ring nitrogen atom
    • C07D207/327—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrrole Compounds (AREA)
DE03713610T 2002-02-15 2003-02-19 Neue kristallformen von atorvastatin-hemicalcium und verfahren zu deren herstellung, sowie neue verfahren zur herstellung der formen i, viii und ix von atorvastatin-hemicalcium Pending DE03713610T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US35718102P 2002-02-15 2002-02-15
US42532502P 2002-11-12 2002-11-12
PCT/US2003/005384 WO2003070702A1 (en) 2002-02-15 2003-02-19 Novel crystal forms of atorvastatin hemi-calcium and processes for their preparation, as well as novel processes for preparing atorvastatin hemi-calcium forms i, viii and ix

Publications (1)

Publication Number Publication Date
DE03713610T1 true DE03713610T1 (de) 2005-10-20

Family

ID=27760457

Family Applications (1)

Application Number Title Priority Date Filing Date
DE03713610T Pending DE03713610T1 (de) 2002-02-15 2003-02-19 Neue kristallformen von atorvastatin-hemicalcium und verfahren zu deren herstellung, sowie neue verfahren zur herstellung der formen i, viii und ix von atorvastatin-hemicalcium

Country Status (14)

Country Link
EP (1) EP1480950A4 (de)
JP (2) JP2005519076A (de)
KR (1) KR100724515B1 (de)
CN (1) CN100406436C (de)
AU (1) AU2003217653A1 (de)
CA (1) CA2475864A1 (de)
DE (1) DE03713610T1 (de)
ES (1) ES2241507T1 (de)
HR (1) HRP20040768A2 (de)
IS (1) IS7402A (de)
MX (1) MXPA04007939A (de)
NO (1) NO20043842L (de)
PL (1) PL372303A1 (de)
WO (1) WO2003070702A1 (de)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7411075B1 (en) 2000-11-16 2008-08-12 Teva Pharmaceutical Industries Ltd. Polymorphic form of atorvastatin calcium
IL156055A0 (en) 2000-11-30 2003-12-23 Teva Pharma Novel crystal forms of atorvastatin hemi calcium and processes for their preparation as well as novel processes for preparing other forms
US7501450B2 (en) * 2000-11-30 2009-03-10 Teva Pharaceutical Industries Ltd. Crystal forms of atorvastatin hemi-calcium and processes for their preparation as well as novel processes for preparing other forms
IL163594A0 (en) 2002-02-19 2005-12-18 Teva Pharma Processes for desolvating solvates of atorvastatinhemi-calcium and atorvastatin hemi-calcium essentially free of organic solvent
AU2003297594A1 (en) * 2002-11-28 2004-06-23 Teva Pharmaceutical Industries Ltd. Crystalline form f of atorvastatin hemi-calcium salt
US7655692B2 (en) 2003-06-12 2010-02-02 Pfizer Inc. Process for forming amorphous atorvastatin
US20050271717A1 (en) 2003-06-12 2005-12-08 Alfred Berchielli Pharmaceutical compositions of atorvastatin
CA2573771C (en) 2004-07-20 2011-05-10 Warner-Lambert Company Llc Novel forms of [r-(r*,r*)]-2-(4-fluorophenyl)-.beta., .gamma.-dihydroxy-5-(1-menthylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1h-pyrrole-1-heptanoic acid calcium salt (2:1)
DE202005020766U1 (de) * 2004-07-22 2006-10-05 Teva Pharmaceutical Industries Ltd. Neue Kristallformen von Atorvastatin-Hemi-Calcium
WO2006048894A1 (en) * 2004-11-05 2006-05-11 Morepen Laboratories Limited Novel crystalline forms of atorvastatin calcium and processes for preparing them.
RU2409563C2 (ru) * 2005-04-08 2011-01-20 Эгиш Дьёдьсердьяр Ньильваношан Мюкёдё Ресвеньтаршашаг Новая полиморфная форма кристаллической гемикальциевой соли аторвастатина
DE602006014193D1 (de) 2005-11-21 2010-06-17 Warner Lambert Co Neue formen von är-(r*,r*)ü-2-(4-fluorphenyl)-b,d-dihydroxy-5-(1-methylethyl)-3-phenyl-4-ä(phenylamino)carbonylü-1h-pyrrol-1-heptansäure-magnesium
KR20100023059A (ko) 2005-12-13 2010-03-03 테바 파마슈티컬 인더스트리즈 리미티드 아토바스타틴 헤미칼슘의 결정형 및 이의 제조 방법
US20070265456A1 (en) * 2006-05-09 2007-11-15 Judith Aronhime Novel crystal forms of atorvastatin hemi-calcium and processes for their preparation as well as novel processes for preparing other forms
EP2132171A4 (de) 2007-03-02 2010-11-17 Dong A Pharm Co Ltd Neue kristalline formen von pyrrolylheptansäurederivaten
KR20120011249A (ko) 2010-07-28 2012-02-07 주식회사 경보제약 아토바스타틴 헤미칼슘염의 신규한 결정형, 이의 수화물, 및 그의 제조방법
KR101324862B1 (ko) * 2011-07-12 2013-11-01 (주)에이에스텍 클로피도그렐 황산수소염의 구형 입자, 이를 포함하는 약학적 조성물 및 이의 제조방법
MX2021001169A (es) 2013-11-15 2023-02-10 Akebia Therapeutics Inc Formas sólidas de ácido {[5-(3-clorofenil)-3-hidroxipiridin-2-carb onil]amino}acético, composiciones, y usos de las mismas.
CN105055357A (zh) * 2015-09-25 2015-11-18 青岛华之草医药科技有限公司 一种治疗高胆固醇血症的药物阿托伐他汀钙组合物片剂
KR101723783B1 (ko) * 2017-02-24 2017-04-07 주식회사 경보제약 아토바스타틴 헤미칼슘염의 신규한 결정형, 이의 수화물, 및 그의 제조방법

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997003959A1 (en) * 1995-07-17 1997-02-06 Warner-Lambert Company Crystalline [r-(r*,r*)]-2-(4-fluorophenyl)-beta,delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1h-pyrrole-1-heptanoic acid hemi calcium salt (atorvastatin)
HRP960313B1 (en) * 1995-07-17 2002-08-31 Warner Lambert Co Form iii crystalline (r- (r*, r*)-2- (4-fluorophenyl) -beta-delta-hydroxy-5-(1-methylethyl) -3-phenyl-4- ((phenylamino) carbonyl -1h-pyrrole-1-heptanoic acid calcium salt (2:1)
US6087511A (en) * 1996-07-16 2000-07-11 Warner-Lambert Company Process for the production of amorphous [R-(R*,R*)]-2-(4-fluorophenyl)-β,δ-dihydroxy-5-(1-methylethyl )-3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrole-1-heptanoic acid) calcium salt (2:1)
YU35802A (sh) * 1999-11-17 2005-07-19 Teva Pharmaceutical Industries Ltd. Polimorfni oblik atorvastatin kalcijuma
MXPA02004078A (es) * 1999-12-17 2002-10-11 Warner Lambert Res & Dev Un proceso a escala industrial para producir sal de hemi calcio de trihidrato de atorvastatin cristalino.
DE60026737T2 (de) * 1999-12-17 2006-09-21 Pfizer Science And Technology Ireland Ltd., Dun Laoghaire Verfahren zur herstellung von kristallin atorvastin kalcium
CA2426632C (en) * 2000-11-03 2008-08-05 Teva Pharmaceutical Industries, Ltd. Atorvastatin hemi-calcium form vii
IL156055A0 (en) * 2000-11-30 2003-12-23 Teva Pharma Novel crystal forms of atorvastatin hemi calcium and processes for their preparation as well as novel processes for preparing other forms
ATE420070T1 (de) * 2000-12-27 2009-01-15 Teva Pharma Kristalline formen von atorvastatin
WO2002057229A1 (en) * 2001-01-19 2002-07-25 Biocon India Limited FORM V CRYSTALLINE [R-(R*,R*)]-2-(4-FLUOROPHENYL)-ß,$G(D)-DIHYDROXY-5-(1-METHYLETHYL)-3-PHENYL-4-[(PHENYLAMINO)CARBONYL]-1H-PYRROLE-1- HEPTANOIC ACID HEMI CALCIUM SALT. (ATORVASTATIN)
EE200300597A (et) * 2001-06-29 2004-02-16 Warner-Lambert Company Llc [R-(R*,R*)]-2-(4-fluorofenüül)-beeta, delta-dihüdroksü-5-(1-metüületüül)-3-fenüül-4-[fenüülamino)karbonüül]-1H-pürrool-1-hepta anhappe kaltsiumsoola (2:1) (atorvastatiini) kristallilised vormid
CZ2004126A3 (cs) * 2001-07-30 2004-12-15 Dr. Reddy's Laboratories Limited Krystalické formy VI. A VII. vápenaté soli atorvastatinu
UA77990C2 (en) * 2001-12-12 2007-02-15 Crystalline calcium salt of (2:1) [r-(r*,r*)]-2-(4-fluorophenyl)-?,?-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1h-pyrroleheptanic acid
EP1562583A1 (de) * 2002-09-03 2005-08-17 Morepen Laboratories Ltd. Atorvastatin kalzium form vi oder dessen hydrate
AU2003297594A1 (en) * 2002-11-28 2004-06-23 Teva Pharmaceutical Industries Ltd. Crystalline form f of atorvastatin hemi-calcium salt

Also Published As

Publication number Publication date
CA2475864A1 (en) 2003-08-28
EP1480950A4 (de) 2005-05-18
CN1646490A (zh) 2005-07-27
JP2005519076A (ja) 2005-06-30
HRP20040768A2 (en) 2005-06-30
AU2003217653A1 (en) 2003-09-09
JP2009235083A (ja) 2009-10-15
NO20043842L (no) 2004-09-14
PL372303A1 (en) 2005-07-11
ES2241507T1 (es) 2005-11-01
EP1480950A1 (de) 2004-12-01
IS7402A (is) 2004-08-13
MXPA04007939A (es) 2004-11-26
CN100406436C (zh) 2008-07-30
KR20040081202A (ko) 2004-09-20
KR100724515B1 (ko) 2007-06-04
WO2003070702A1 (en) 2003-08-28

Similar Documents

Publication Publication Date Title
DE03713610T1 (de) Neue kristallformen von atorvastatin-hemicalcium und verfahren zu deren herstellung, sowie neue verfahren zur herstellung der formen i, viii und ix von atorvastatin-hemicalcium
DE60308596D1 (de) Verfahren zur Herstellung von anorganisichen Nanoröhren
DE60301350D1 (de) Verfahren zur herstellung von 7-substituierten -3-chinolin und 3-chinol-4-on carbonitrile
DE60330341D1 (de) Verfahren zur herstellung von wabenstrukturen
DE60223032D1 (de) Vorrichtung zur herstellung von verbundkonstruktionen und verfahren zur herstellung derselben
DE60224643D1 (de) Verfahren zur herstellung von reifen
DE60216108D1 (de) Vorrichtung zur herstellung von verbundstrukturen und verfahren zu deren herstellung
DE60217860D1 (de) Verfahren zur herstellung von haftverschlüssen
DE50000852D1 (de) Verfahren zur Herstellung von Aminen
DE60326628D1 (de) Dorn und verfahren zur herstellung von stents
DE60225539D1 (de) Verfahren zur kontinuierlichen herstellung von polyarylensulfid
DE60104810D1 (de) Zellfreies Verfahren zur Herstellung von posttranslational veränderten Proteinen
DE60333291D1 (de) Verfahren zur herstellung von flachglas
DE60331571D1 (de) Verfahren zur herstellung von poröser wabenstruktur und wabenkörper
DE602004020895D1 (de) Verfahren zur herstellung von kohlenstoffnanospulen
DE60024705D1 (de) Reaktionsvorrichtung zur Herstellung von Alkanolamin sowie Verfahren zur Alkanolaminherstellung mit Verwendung der Vorrichtung
DE60307830D1 (de) Neue multimerische moleküle, verfahren zu deren herstellung, und deren verwendung zur herstellung von arzneimitteln
DE50308650D1 (de) Verfahren zur herstellung von cellulosecarbamatformkörpern
ATE316959T1 (de) Verfahren zur herstellung von 2- halogenpyridincarbonsäureamiden
ATE441662T1 (de) Verfahren zur herstellung von echinocandinderivaten
DE50303611D1 (de) Verfahren zur herstellung von polyisobuten
DE50311487D1 (de) Verfahren zur Herstellung von Kompositmembranen
DE60210778D1 (de) Verfahren zur herstellung von 4-amino-2,5-bisheterocyclylchinazolinen
DE60300144D1 (de) Verfahren zur Herstellung von Al-Sinterlegierung
ATE350363T1 (de) Verfahren zur herstellung von alpha- hydroxycarbonsäure amiden